drugset / Trial / NCT04364048
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Phase 2
Terminated
10 enrolled
Rachel Sanborn
AstraZeneca · collabProvidence Cancer Center, Earle A. Chiles Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
Single arm study of induction durvalumab (1500 mg IV) for 1 cycle (every 4 weeks), administered prior to starting concurrent definitive chemoradiation, followed by consolidation durvalumab (1500 mg IV every 4 weeks) for up to 12 cycles. The study will include an initial safety run-in portion. Patients in the safety run-in will be monitored through completion of induction durvalumab, chemoradiation, and 2 cycles of consolidation durvalumab for assessment of safety prior to completion of enrollment.
Timeline
- Start
- 2020-06-18
- Primary completion
- 2023-06-20
- Completion
- 2024-02-05
Outcome
Outcome not reported
Stopped (Enrollment): “Study enrollment was halted due to pandemic-related slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |